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Abstract
Background: Gastrointestinal stromal tumors (GISTs) are morphologically and clinically heterogeneous tumors, and
their biological behavior is difficult to predict, ranging from clinically benign to malignant. The aim of our study
was to reanalyze the value of the commonly used prognostic criteria and recently reported nomogram in
predicting disease recurrence in patients with primary resectable GISTs.
Methods: The clinicopathological features of 60 patients with GISTs who underwent surgical resection between
1998 and 2010 at Hiroshima University Hospital were retrospectively reviewed. Tumors were classified according to
the National Institutes of Health and Armed Forces Institute of Pathology criteria, and nomogram predictions were
performed. The relationship between patient and tumor characteristics was tested by univariate analysis using the
log-rank test. Furthermore, we assessed nomogram performance with the concordance index and calibration.
Results: The median patient follow-up was 4.1 years, with 6 of 60 patients experiencing recurrence. Recurrence
was observed only in the high-risk group. The recurrence-free survival (RFS) was 93.0 and 89.9% after 2 and 5 years,
respectively. The concordance indices of the nomogram prediction were 0.96 and 0.65 for all patients and the
high-risk subgroup, respectively. Calibration of the nomogram-predicted RFS tended to overestimate the recurrence
risk relative to the actual RFS.
Conclusions: Although the commonly used criteria provide an excellent estimation of tumor behavior, they are
limited by prognostic heterogeneity. The predictive nomogram is a beneficial scoring system but not a direct RFS
predictor. We need more consideration for small GISTs, particularly those less than 3 cm in diameter, and small
GISTs should be analyzed as a subset with potentiality different biological behavior.
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Background
Gastrointestinal stromal tumor (GIST) is the most com-
mon mesenchymal neoplasm of the intestinal tract. The
tumor typically occurs in the stomach or small intestine,
infrequently in the colon, rectum, and esophagus, and
rarely outside the gastrointestinal tract. The gold stan-
dard therapy for localized primary GIST is surgical
resection [1,2]. Unfortunately, the results of surgery
alone have been inadequate, with up to 50% of patients
developing tumor recurrence within 5 years and even-
tually dying from the disease [3-5].
In 2000, imatinib mesylate (Novartis Pharmaceuticals,
Basel, Switzerland) was found to be effective against
metastatic GIST in the initial patient tested [6], and its
efficacy was then confirmed in a phase II [7,8] and in
phase III trials [9,10]. In 2009, the American College of
Surgeons Oncology Group (ACOSOG) reported the
results of study Z9001, a randomized control trial asses-
sing the efficacy of adjuvant imatinib for patients with
primary GISTs larger than 3 cm [11]. More recently, at
the American Society of Clinical Oncology (ASCO) 47th
Annual Meeting, the results of the SSG XVIII-AIO
study were presented. This phase III trial revealed that 3
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years of treatment with imatinib after surgery in patients
with high-risk GIST according to the National Institutes
of Health (NIH) criteria [12], including patients who
had tumor rupture before or during surgery, improved
overall and recurrence-free survival (RFS) compared to
the finding after 1 year of treatment.
GISTs are morphologically and clinically heteroge-
neous tumors, and their biological behavior is difficult
to predict, ranging from clinically benign to malignant.
The NIH criteria are based on the evaluation of the size
and mitotic rate of the tumors as the most reliable prog-
nostic factors, and their use is common. Another set of
commonly used criteria that considers a third prognostic
factor–tumor location–was proposed by the Armed
Forces Institute of Pathology (AFIP) [13,14]. In addition,
Gold et al. reported that their prognostic nomogram
provided a better prediction of the likelihood of recur-
rence for individual patients in Western datasets than
the commonly used staging criteria that stratify patients
into a few broad groups [15].
The aim of our study was to reanalyze the value of the
prognostic criteria regarding their relationship to disease
recurrence in patients with primary resectable GISTs in
our prospectively collected tumor registry as a Japanese
dataset.
Methods
From 1998 to 2010, 60 patients presented to our institu-
tion with primary GIST without metastasis. Patient,
tumor, and treatment data were collected prospectively.
Complete gross resection of the tumor was performed
in all patients. The technique of resection was at the
discretion of the individual surgeon. An expert patholo-
gist confirmed the diagnosis of GIST and calculated the
mitotic index. The diagnosis of GIST was confirmed by
immunohistochemical staining for CD117. The mitotic
index was determined by counting the number of mito-
tic figures per 50 high-power fields (HPFs) and categor-
ized as less than 5 or 5 or more mitoses. Size
measurements were performed by the institutional
pathologists, either before or after formalin fixation, and
tumors were categorized as 5 cm or less or more than 5
cm in diameter. Tumors were classified according to the
NIH and AFIP criteria, which are 2 commonly used sets
of criteria (Table 1). Simultaneously, nomogram predic-
tions were performed for the tumors [15]. The nomo-
gram assigned points based on tumor size in a
continuous but non-linear fashion. Points for tumor site
were assigned on the basis of whether the tumor arose
in the stomach, small intestine, colon/rectum, or an
extraintestinal location, and points for mitotic index
were assigned on the basis of whether the primary
tumor had less than 5 or 5 or more mitoses per HPF
(Figure 1). No patient was treated with a tyrosine kinase
inhibitor before developing recurrence. As a follow up
study, chest and abdominal computed tomography (CT)
scans were performed at least every 6 months after sur-
gery on patients with greater than intermediate- or
moderate-risk, and at least every year on patients with
very low- or low-risk. However, CT scans were repeated
earlier whenever clinically indicated depending on the
discretion of the investigator. Endoscopy was performed
annually. Patients did not undergo any further selection.
Follow-up information was obtained during regular out-
patient visits or by phone with the patient and/or the
referring physician. During follow-up, we analyzed the
incidence of disease recurrence. All deaths from other
causes were recorded. RFS was defined as the time from
patient registration to the development of tumor
recurrence.
We estimated RFS probabilities with the Kaplan-Meier
method. The relationships of patient and tumor charac-
teristics to outcome were investigated by univariate ana-
lysis using the log-rank test. Multivariate analysis could
not be performed because of the small number of recur-
rence events. A p-value of < 0.05 was considered statisti-
cally significant. SPSS statistical software (v.18; Chicago,
IL, USA) was used for univariate analysis.
We assessed nomogram performance in 2 ways. First,
the discriminatory capability of the nomogram was
determined using the concordance index (C index) [16].
The interpretation of the C index is similar to that of
Table 1 Commonly used criteria for assessing risk of GIST
NIH criteria14
Very low < 2 cm and < 5 mitotic index
Low 2-5 cm and < 5 mitotic index
Intermediate 5-10 cm and < 5 mitotic index
> 5 cm and 6-10 mitotic index or
High > 5 cm and > 5 mittic index or
> 10 cm and any mitotic index or
Any size and > 10 mitotic index
AFIP criteria16, 17
Unknown * Expect from following criteria
Very low ≦ 5 cm and ≦ 5 mitotic index
Low Gastric: > 5 cm and ≦ 10 cm and ≦ 5 mitotic index
Others: > 2 cm and ≦ 5 cm, and ≦ 5 mitotic index
Moderate Gastric: > 10 cm and ≦ 5 mitotic index or
> 2 cm and ≦ 5 cm, and > 5 mitotic index
Others: > 5 cm and ≦ 10 cm, and ≦ 5 mitotic index
High Gastric: > 5 cm and > 5 mitotic index
Others: > 10 cm or > 5 mitotic index
* Category with small numbers of cases insufficient for prediction of
malignant potential
NIH: the National Institutes of Health
AFIP: the Armed Forces Institute of Pathology
Definition for risk categories in the National Institutes of Health and Armed
Forces Institute of Pathology criteria.
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the area under the receiver operating characteristic
curve. The C index provides the probability that the
nomogram will predict a poorer outcome for the patient
who recurred first out of a randomly selected pair of
patients. The C index was assessed with respect to 3
groups: all patients, a subgroup excluding very low- and
low-risk patients, and a subgroup limited to patients
whose tumors were classified as high-risk by either NIH
or AFIP criteria. Second, calibration was evaluated by
comparing the Kaplan-Meier-observed RFS for 4 quar-
tiles of patients stratified by nomogram score 2 years
after surgical treatment. Calibration was limited to the
2-year RFS because the median follow-up period was
insufficient to estimate the 5-year RFS.
Results
The detailed clinicopathological features of the patients
with primary GISTs are shown in Table 2. The median
age of the patients was 63 years (range, 18-83 years),
and 31 patients (51.7%) were men. Tumor locations
included the stomach, small intestine, and rectum in 48
(80%), 11 (18.3%), and 1 (1.7%) patient, respectively. The
median tumor size was 3.8 cm (range, 1.6-20 cm). The
median duration of follow-up for patients in this series
was 4.1 years (range 0.1-12.8 years), with 6 of 60
patients experiencing recurrence. Five of six patients
had disease recurrence in the liver, and another had
local intrapelvic recurrence. All of these recurrences
were detected by follow-up CT scan, with 4 of the
recurrence events occurring less than 1 year after sur-
gery. Three patients were lost to follow-up before 2
years. All 3 patients lost to follow-up had very low- or
low-risk tumors. According to the NIH criteria, 34
(56.6%), 13 (21.7%), and 13 (21.7%) tumors were classi-
fied as very low- or low-, intermediate-, and high-risk,
respectively. According to the AFIP criteria, 3 (5.0%), 35
(58.3%), 13 (21.7%), and 9 (15%) tumors were classified
as unknown, very low or low, moderate, and high risk,
respectively. In the univariate analysis, size and the
mitotic index predicted RFS (p = 0.002). When correlat-
ing recurrence with tumor location, a trend toward sta-
tistical significance became evident (p = 0.051).
RFS was 93.0% (SE 0.034%), and 89.9% (SE 0.045%)
after 2 and 5 years, respectively (Figure 2). In our series,
the 2-year and 5-year RFS was better than that reported
previously. RFS-classified risk groups according to the
NIH and AFIP criteria are shown in Figure 3. Recur-
rence events were observed only in the groups classified
as high risk by either set of criteria.
Next, we estimated the discriminatory capability of the
nomogram by using the C index. The C index of the
nomogram prediction for all patients was 0.96, which
was adequately acceptable. The C indices of the nomo-
gram predictions excluding the low-risk subgroup and
limited to only the high-risk subgroup were 0.91 and
0.65, respectively. Therefore, in 65% of the cases, the
nomogram correctly predicted the order of outcome
between 2 randomly selected patients who were classi-
fied as high-risk according to either the NIH or AFIP
criteria. A calibration test was performed to estimate the
accuracy of the RFS predicted by the nomogram. Cali-
bration of the nomogram-predicted RFS tended to over-
estimate recurrence compared with the Kaplan-Meier-
observed RFS (Figure 4).
Discussion
In our series, 2-year and 5-year RFS was better than that
previously reported (93.0% and 89.9%, respectively).
There were a large proportion of very low- and low-risk
patients. The reasons for the large proportion of low-
risk GISTs may be the excellent screening system and
the early indication for surgery. Simply, this may mean
that early diagnosis and resection improve the overall
survival. Meanwhile, our dataset had an obviously high
proportion of smaller tumors than Western datasets.
Because of their high mitotic indices, some “small”
Figure 1 Prognostic nomogram adapted from Gold et al. [15]. Points are assigned for size, mitotic index, and site of origin by drawing a line
upward from the corresponding values to the “Points” line. The sum of these 3 points, plotted on the “Total points” line, corresponds to
predictions of 2- and 5-year recurrence-free survival. HPF: high-power fields.
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GISTs less than 3 cm in diameter were classified as
intermediate- or high-risk tumors. The proportion of
“small” GISTs may account for the better prognosis
compared to those observed in Western datasets.
Currently, accurate prognostication of GISTs is essen-
tial, not only in guiding the clinician regarding the fre-
quency and intensity of postoperative surveillance but
also, to enable better selection of tumors for potential
adjuvant treatment. In current clinical practice, relatively
large numbers of clinicians appear to recommend adju-
vant imatinib therapy for patients with high-risk tumors
according to the NIH criteria. In the ACOSOG Z9001
trial, one of the few studies of adjuvant imatinib therapy,
patients were only stratified according to tumor size,
which may not be the only prognostic factor in recent
studies, making it difficult to adequately select patients
for whom the adjuvant treatment could be clearly bene-
ficial. In 2010, at the Gastrointestinal Cancers Sympo-
sium (ASCO-GI), Blackstein et al. reported a stratified
analysis of the Z9001 trial using the AFIP criteria. [17]
The 2-year RFS of the low-risk patients was 98% and
thus, there was no benefit of adjuvant therapy. The
recurrence rate of the high-risk patients selected with 3
factors–tumor size, mitotic index, and tumor location–
was the highest and the high-risk patients gained the
greatest effect from imatinib adjuvant therapy. The
importance of these 3 factors was also suggested in our
present study. Simultaneously, recurrence events were
observed only in the group classified as high risk by
both the NIH and AFIP criteria and many of these
events occurred during the first postoperative period.
This result indicates that commonly used criteria
Table 2 Characteristics of 60 patients with primary resectable GISTs
Clinicopathological feature n (total = 60) Recurrence events (n = 6) univariate analysis P value
Follow up period (years)
median (range) 2.8 (0.1-11.8)
Sex
Female 29 2
Male 31 4 0.465
Age (years)
median (range) 63 (18-83)
≦ 63 31 5
> 63 29 1 0.211
Tumor location(%)
Stomach 48 (80) 3
Others 12 (20) 3 0.51
Tumor size (cm)
median (range) 3.8 (1.6-20)
≦ 5 43 1
> 5 17 5 0.002
Mitotic index*
< 5 39 0
≧ 5 21 6 0.002
Resection margin
R0 51 4
R1 9 2 0.156
NIH criteria (%)
Very low & Low 34 (56.6) 0
Intermediate 13 (21.7) 0
High 13 (21.7) 6
AFIP criteria (%)
Unknown 3 (5.0) 0
Very low & Low 35 (58.3) 0
Moderate 13 (21.7) 0
High 9 (15) 6
*Mitotic index = number of mitoses per 50 high-power fields.
NIH the National Institutes of Health
AFIP the Armed Forces Institute of Pathology
Detailed clinicopathological features of the patients with primary GISTs and the results of univariate analysis.
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provide an excellent estimation of tumor behavior.
However, regarding adjuvant therapy, the high-risk
patients classified by the commonly used criteria do not
always include patients who can benefit fully from the
use of adjuvant therapy. Huang et al. clearly revealed
the limitations of these criteria [4]. The high-risk
category has been criticized as being too heterogeneous.
According to the results of the SSG XVIII-AIO study, if
a long duration of adjuvant therapy is recommended to
all high-risk patients, the adverse effects of imatinib
adjuvant therapy are not negligible. Considering the















Figure 2 Recurrence-free survival of total patients. Kaplan-Meier estimates of the recurrence-free survival of patients with primary GIST after
complete surgical resection.






































Figure 3 Recurrence-free survival classified using commonly used criteria. A. Kaplan-Meier estimates of recurrence-free survival of primary
resectable GIST patients classified according to NIH criteria. B. Kaplan-Meier estimates of recurrence-free survival of primary resectable GIST
patients classified according to AFIP criteria.
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indications for long adjuvant therapy are patients who
are expected to develop recurrence in the early period
after surgery. We experienced 3 “small” GISTs less than
3 cm in diameter that were classified as high-risk GISTs
according to the NIH or AFIP criteria. The patients
with these tumors had no recurrences at 1.7, 4.3, and
6.5 years after surgery, respectively. In a practical sense,
it is difficult to decide whether adjuvant therapy is
necessary for these patients. Naturally, the potential for
recurrence and metastasis is lower for smaller tumors.
In particular, the Z9001 trial did not reveal the benefit
of adjuvant imatinib for small GISTs less than 3 cm,
and this minor subset has not been analyzed adequately
in Western countries. It is expected that adjuvant ther-
apy for GISTs will be more individualized. Concerning
adjuvant therapy, we need more consideration for small
GISTs, and small GISTs should be analyzed as a subset
with potentially different biological behavior.
Nomograms can estimate tumor size in a continuous
but nonlinear fashion and calculate the risk of recur-
rence at a point in time for any individual patient. No
other staging system has been assessed for its ability to
assign a quantitative risk of recurrence for individual
patients. It might be challenging to justify the use of
adjuvant imatinib by nomogram prediction alone
because the nomogram prediction overestimated the
recurrence risk compared with the actual RFS in our
series. However, the discriminatory capability of the
nomogram for the subgroup of high-risk patients is
worthy of attention (C index = 0.65).
When interpreting the results of the current analysis,
it is important to consider the limitation of our dataset.
The small sample size of a single center experience is
not sufficient to validate and decide the cut-off value.
However, we can suggest the nomogram as a beneficial
scoring system in practical situations, but not as a direct
RFS predictor.
In addition, the prognostic criteria could be improved
with the incorporation of additional variables, for exam-
ple, mutation status. Gold et al. failed to observe an
improvement in the accuracy of the nomogram predic-
tion when mutation status was included [15]. However,
conflicting results exist about whether KIT and platelet-
derived growth factor receptor alpha (PDGFRA) muta-
tion status affect outcome among patients with resected
localized primary GISTs [18-26]. Approximately 85% of
GISTs contain an activating mutation in the KIT proto-
oncogene, whereas 3-5% of patients have a PDGFRA
mutation [12,27,28]. Moreover, the effect of imatinib
varies depending on the domains of KIT and PDGFRA
affected by the mutations. Therefore, many uncertainties
remain regarding techniques to assess prognostic fac-
tors, including whether tumor size should be measured
before or after fixation and whether the most mitotically
active tumor areas should be assessed, as well as regard-
ing the dosage and duration of imatinib adjuvant ther-
apy. Given these uncertainties, longer follow-ups and
results from additional trials are needed.
Conclusions
Although the commonly used criteria provide an excel-
lent estimation of tumor behavior, they are limited by
the prognostic heterogeneity of their high-risk tumor
categories. The predictive nomogram is a beneficial
scoring system but not a direct RFS predictor. We need
more consideration for small GISTs, particularly those
less than 3 cm in diameter, and small GISTs should be
analyzed as a subset with potentially different biological
behavior.
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Figure 4 Calibration of nomogram-predicted recurrence-free
survival (RFS). Observed RFS is shown compared with nomogram-
predicted RFS at 2 years.
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